Medical Scientist Training Program

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Retrieved on: 
Tuesday, September 19, 2023
Lewis & Clark College, University, Therapy, Internal medicine, Medical Scientist Training Program, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Cancer, Liver cancer, Oncology, Research and development, Development, Patient, University of Washington School of Medicine, Microbiology, Renal cell carcinoma, Pharmaceutical industry, Tempest, Chemistry, Research

Ph.D., has expanded his role to include head of Research and Development.

Key Points: 
  • Ph.D., has expanded his role to include head of Research and Development.
  • Our preclinical and translational sciences fuel the company’s robust pipeline, while providing key insight into our clinical programs.
  • Dr. Whiting completed fellowship training in medical oncology at the Fred Hutchinson Cancer Research Center.
  • and Ph.D in microbiology in the Medical Scientist Training Program at the University of Washington.

CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

Retrieved on: 
Thursday, August 24, 2023
Pediatrics, UCLA Mattel Children's Hospital, Education, Cancer, Light, Research, Medical Scientist Training Program, Biomedical engineering, Science, Regenerative medicine, Physician, Engineering, Hematology, UCLA, NIH, Pharmaceutical industry, LEHI

LEHI, Utah, Aug. 24, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher.

Key Points: 
  • LEHI, Utah, Aug. 24, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher.
  • I hope this can be our contribution.”
    CancerVAX CEO Ryan Davies said, “It has been a great pleasure getting to know Steve through our work together with CancerVAX and UCLA.
  • As we continue our fight against cancer, it’s wonderful knowing we are working with some of the world’s best like Steve”.
  • This Podcast can be viewed at: https://www.youtube.com/watch?v=LTzE5Y78RrU
    For more information about CancerVAX, please visit http://www.cancervax.com/

Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research

Retrieved on: 
Wednesday, December 7, 2022
Biotechnology, Health, Science, Research, Oncology, Faculty, Baylor College of Medicine, Society, Therapy, Gene, Cytokine, SITC, Breast cancer, UPMC Hillman Cancer Center, Johns Hopkins University, Baltimore metropolitan area, Immunotherapy, National Cancer Institute, Medical Scientist Training Program, Cancer immunology, University of Pittsburgh Medical Center, Patient, Cancer, Toxicity, ASCO, Society for Immunotherapy of Cancer, Medicine, YWCA, AACR, Baylor University, University, Inflammation, CIMM, UPMC, Stand Up, Moses Austin, Pharmaceutical industry, Vaccine

Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research.

Key Points: 
  • Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research.
  • With a particular focus on immunotherapy and having held positions at some of the worlds leading academic institutions, Leisha is the ideal person to fill this role.
  • Dr. Emens is a medical oncologist focused on breast cancer and is internationally recognized for her work in breast cancer immunotherapy.
  • Ankyra Therapeutics is a biotechnology company developing a novel approach to treating cancer, designed to expand the therapeutic window of cytokine drugs.

Cytokinetics Reports Fourth Quarter 2021 Financial Results

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Risk, Mercury (element), Blood, File, Cohort, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Heart Association, New Drug Application, HF, Investment, American College, Heart, Clinical study design, AHA, Stroke, Cardiology, CPET, Heart failure, Food, Exercise, Obstruction, PDUFA, Safety, FDA, Medical Scientist Training Program, Cytokinetics, Patient, Â, NDA, Disopyramide, Pharmaceutical industry, HCM

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2021. Net loss for the fourth quarter was $30.6 million or $0.36 per share and the net loss for the year 2021 was $215.3 million or $2.80 per share. Net loss for the fourth quarter of 2020 was $43.9 million or $0.62 per share and net loss for the year 2020 was $127.3 million or $1.97 per share. Cash, cash equivalents and investments totaled $623.7 million at December 31, 2021. This cash balance does not include $150 million in proceeds received from transactions executed in late 2021 and early 2022.

Key Points: 
  • Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022
    Company Provides 2022 Financial Guidance;
    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2021.
  • Members of Cytokinetics senior management team will review the companys fourth quarter results on a conference call today at4:30 PM Eastern Time.
  • For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission, particularly under the caption Risk Factors in Cytokinetics Quarterly Report on Form 10-Q for the third quarter 2021.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

National Marrow Donor Program®/Be The Match® Awards Amy Strelzer Manasevit Research Program Grant to Dan Peltier, MD, PhD

Retrieved on: 
Monday, February 7, 2022
Multiple myeloma, GVHD, Senior, Friends, Lists of scientists, Children's Hospital, Medical Scientist Training Program, Multimedia, Doctor of Philosophy, Research, Michigan State University, Memory, NMDP, American Society of Pediatric Hematology/Oncology, National Confidential Enquiry into Patient Outcome and Death, Quality of life, University, Graft-versus-host disease, Patient, Listeria monocytogenes non-coding RNA, Medical College of Wisconsin, Transplant, Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Hospital, Hematology, Center, Hematopoietic stem cell transplantation, Pediatrics, RNA, Pneumonia, Experience, Immunology, Society, View, Oncology, Pharmaceutical industry, Dentistry, Match, Microbiology, MD

MINNEAPOLIS, Feb. 7, 2022 /PRNewswire/ --The National Marrow Donor Program(NMDP)/Be The Match, a global leader in cellular therapy, awarded this year's Amy Strelzer Manasevit Research Program grant to Dan Peltier, MD, PhD.

Key Points: 
  • MINNEAPOLIS, Feb. 7, 2022 /PRNewswire/ --The National Marrow Donor Program(NMDP)/Be The Match, a global leader in cellular therapy, awarded this year's Amy Strelzer Manasevit Research Program grant to Dan Peltier, MD, PhD.
  • The Amy Strelzer Manasevit Research Program, among the largest and most coveted grants in the transplant and cellular therapy field, supports the research efforts of scientists and clinicians early in their careers.
  • Visit our website to learn more about the Amy Strelzer Manasevit Research Program and the many ways NMDP/Be The Match supports transplant and cellular therapy research.
  • The National Marrow Donor Program(NMDP)/Be The Match is the leading global partner working to save lives through cellular therapy.

Cytokinetics Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 3, 2021
Medical Affairs Bureau, Research, Clinical study design, Cytokinetics, Manuscript, CO, Medical Scientist Training Program, Patient, American Heart Association, Medical director, Marketing, Investment, Journal of the American Heart Association, NDA, JAMA Cardiology, Cohort, GLOBE, Heart Failure Society of America, Heart failure, HF, Journal, Cardiology, Pharmaceutical industry, Medical device

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2021. Net loss for the third quarter was $76.1 million, or $0.95 per share, compared to net loss for the third quarter of 2020 of $3.2 million, or $0.05 per share. Cash, cash equivalents and investments totaled $668.9 million at September 30, 2021.

Key Points: 
  • Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022
    SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2021.
  • Members of Cytokinetics senior management team will review the companys third quarter results on a conference call today at4:30 PM Eastern Time.
  • An archived replay of the webcast will be available via Cytokinetics website until November 17, 2021.
  • For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission, particularly under the caption Risk Factors in Cytokinetics latest Quarterly Report on Form 10-Q.

Harrington Discovery Institute at University Hospitals and Case Western Reserve School of Medicine Open Call for 2022 Harrington-MSTP Scholar Award

Retrieved on: 
Friday, October 29, 2021
Technology, University Hospitals Cleveland Medical Center, Medical Scientist Training Program, Lists of scientists, Letter, School, Case Western Reserve University School of Medicine, MSTP, Intention, Discovery, Discovery Institute, Biochemistry, Development, Health, Doctor of Philosophy, Student, Pharmaceutical industry

CLEVELAND, Oct. 29, 2021 /PRNewswire/ --Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine have issued a call for proposals for the 2022 Harrington-MSTP (Medical Scientist Training Program) Scholar Award to help the next generation of physician-scientists advance their discoveries towards clinical application.

Key Points: 
  • CLEVELAND, Oct. 29, 2021 /PRNewswire/ --Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine have issued a call for proposals for the 2022 Harrington-MSTP (Medical Scientist Training Program) Scholar Award to help the next generation of physician-scientists advance their discoveries towards clinical application.
  • Since its founding in 2012, Harrington Discovery Institute part of The Harrington Project for Discovery & Development has supported nearly 150 drugs-in-the-making in the U.S., Canada and the U.K.
  • Core to its mission, Harrington Discovery Institute recognizes and supports inventive physician-scientists seeking to elevate the standard of care in medicine.
  • Through this award, Harrington Discovery Institute and the School of Medicine combine resources and capabilities to advance into new medicines the most promising independent discoveries of Case Western Reserve MD/PhD candidates.

Robert H. Odell Jr., MD, PhD, is recognized by Continental Who's Who

Retrieved on: 
Wednesday, September 8, 2021

Dr. Odell is the Owner and Medical Director of Neuropathy and Pain Centers of America, located in Las Vegas.

Key Points: 
  • Dr. Odell is the Owner and Medical Director of Neuropathy and Pain Centers of America, located in Las Vegas.
  • To provide the best results for each patient, Dr. Odell uses advanced electromedical devices that can produce favorable outcomes for treating neuropathy and other difficult-to-treat pain management challenges.
  • Dr. Odell did a residency at Anesthesiology at UCLA, then served as Chief Resident at Harbor/UCLA Medical Center.
  • When he is not treating patients, Dr. Odell loves to run and play with his three yellow labs.

Harrington Discovery Institute At University Hospitals And Case Western Reserve School Of Medicine Open Call For 2021 Harrington-MSTP Scholar Award

Retrieved on: 
Tuesday, November 10, 2020
Case Western Reserve University, University Circle, Jonathan Stamler, Education, V-12 Navy College Training Program, University Hospitals Cleveland Medical Center, Medical Scientist Training Program, Case Western Reserve University School of Medicine, Harrington, Cleveland

CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine have issued a call for proposals for the 2021 Harrington-MSTP (Medical Scientist Training Program) Scholar Award to help the next generation of physician-scientists advance their discoveries into breakthrough medicines.

Key Points: 
  • CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine have issued a call for proposals for the 2021 Harrington-MSTP (Medical Scientist Training Program) Scholar Award to help the next generation of physician-scientists advance their discoveries into breakthrough medicines.
  • Since its founding in 2012, Harrington Discovery Institute--part of The Harrington Project for Discovery & Development--has supported 137 drugs-in-the-making in the US, Canada and the United Kingdom.
  • Through this award, Harrington Discovery Institute and the School of Medicine combine resources and capabilities to advance into new medicines the most promising research of Case MSTP students.
  • We are pleased to work closely with Case Western Reserve University to provide this opportunity," said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair of Cardiovascular Innovation and Professor of Medicine at University Hospitals and Case Western Reserve University.